Observational studyEuropean journal of clinical pharmacology2020
Methods for constructing treatment episodes and impact on exposure-outcome associations.
Observational study in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review.ESMO real world data and digital oncology · 2026Review
- An operational target trial emulation framework for causal inference using electronic health record data.NPJ digital medicine · 2026Review
- A methodological framework for constructing opioid agonist therapy episodes in administrative health data.BMC methods · 2026Article
- Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.Cancer · 2025Article
- Differential use of antidiabetic medication related to income, cohabitation and area of residence: a Swedish nationwide cohort study.Journal of epidemiology and community health · 2025Article
- Longitudinal Trajectories of Antidiabetic Medication Adherence Over 5 Years From Treatment Initiation-A Swedish Nationwide Cohort Study.Clinical and translational science · 2025Article
- Use of electronic health record data to examine administrations of pro re nata analgesics during hip fracture post-acute care.Pharmacoepidemiology and drug safety · 2024Article
- Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database.European journal of neurology · 2024Article
- Article
- Persistence to Medications for Benign Prostatic Hyperplasia/Benign Prostatic Obstruction-Associated Lower Urinary Tract Symptoms in the ASL TO4 Regione Piemonte (Italy).Healthcare (Basel, Switzerland) · 2022Article
- Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources.Scientific reports · 2022Article
- Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis.Journal of personalized medicine · 2022Article
- Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis.International journal of environmental research and public health · 2021Article
- Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sources.European journal of clinical pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
purposeTo assess the impact on exposure time and outcome misclassifications, and consequent impact on exposure-outcome associations from treatment episode construction. We investigated the dosage assumptions of 1 unit per day, and 1 DDD per day, versus actual prescribed dosage under different handling of gaps and overlaps of prescriptions.
methodsData on mirtazapine and citalopram exposure (years 2006-2014) from the Swedish Prescribed Drug register were used. Via a within individuals design we compared method A, based on actual dosage, with methods B and C based on 1 unit of drug per day and 1 DDD per day assumptions, respectively, including consideration of gaps and overlaps. Four outcomes were used, hospitalizations and outpatient visits for all and for psychiatric causes.
resultsRelative to method A, both alternative methods lead to misclassification of exposure time. With regard to outcome misclassifications, method B overestimates the effect of the exposure on the outcome in 77% and 100% of exposure definition comparisons for mirtazapine and citalopram respectively, while 23% of the comparisons for mirtazapine results in underestimation of exposure-outcome associations. Conversely, treatment episodes based on DDD (method C) result in underestimation of the exposure-outcome association in 100% and 87.5% of exposure definition comparisons for mirtazapine and citalopram respectively, while 12.5% of the comparisons for citalopram results in overestimation of the exposure-outcome associations.
conclusionsThe study provides results that have consistent clinical relevance. We have showed that a non-accurate construction of exposure time may lead to errors on outcome detection during exposed time, and consequently affect conclusions on safety or efficacy profile of a treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.